Clinical Trials Logo

Pulmonary Hypertension clinical trials

View clinical trials related to Pulmonary Hypertension.

Filter by:

NCT ID: NCT03012646 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Start date: April 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT02999438 Completed - Heart Failure Clinical Trials

Frailty in Children With Cardiac Disease

Start date: November 2016
Phase:
Study type: Observational

Frailty is a complex biologic syndrome of diminished physiologic reserve that leads to decreased resistance to stressors and is associated with adverse health outcomes. The syndrome has been well studied in adults and is quantified by the Fried criteria, which are comprised of five components- slowness, weakness, self-reported exhaustion, shrinkage and diminished physical activity. The concept of frailty is novel in children. A study in young adult childhood cancer survivors demonstrated increased incidence of frailty in this population along with increased risk of morbidity and mortality. This suggests that frailty as a phenotype has relevance outside of the geriatric age group. Pediatric patients with single ventricle physiology, heart failure and pulmonary artery hypertension- all represent populations with significantly increased risk of mortality, morbidity and decreased quality of life. Currently, such patients are monitored outpatient by serial echocardiograms and blood work that only gives information about end organ damage. But there is no validated tool available to measure global infirmity in such children. Better understanding of the relevance and applicability of frailty in pediatrics may allow for identification of the most vulnerable pediatric cardiac patients and be of value in optimizing their clinical management and improving health outcomes.

NCT ID: NCT02986087 Recruiting - Clinical trials for Congenital Diaphragmatic Hernia

Feto-Endoscopic Tracheal Occlusion (FETO) for Left Congenital Diaphragmatic Hernia

FETO
Start date: November 2016
Phase: N/A
Study type: Interventional

Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses.

NCT ID: NCT02981082 Terminated - Systemic Sclerosis Clinical Trials

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Start date: December 2016
Phase: Phase 1
Study type: Interventional

A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients. The study will determine safety and the primary outcome variability for DMF in treating SSc-PAH; the primary outcome of clinical efficacy in this pilot trial will be improvement in 6-minute walk distance (6MWD).

NCT ID: NCT02980068 Completed - Heart Failure Clinical Trials

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

PMED
Start date: August 28, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in healthy adult normal volunteers compared to volunteers with PH-HFpEF in the breakdown of oral nitrate.

NCT ID: NCT02966899 Withdrawn - Clinical trials for Right Ventricular Failure

Reversal of Right Ventricular Steatosis in Pulmonary Hypertension

Start date: November 2016
Phase: N/A
Study type: Interventional

The goal of this study is to elucidate the relationship between myocardial right ventricular triglyceride content (steatosis) and right ventricular dysfunction in participants with pulmonary hypertension, and investigate reversibility of this phenotype with omega-3 fatty acid treatment.

NCT ID: NCT02951104 Completed - Clinical trials for Pulmonary Hypertension

Noninvasive Cardiac Output Monitoring in Pulmonary Hypertension

Start date: November 2016
Phase: N/A
Study type: Interventional

Comparison of Ultrasonic Cardiac Output Monitor (USCOM) system with Fick and thermodilution methods during right heart catheterization in patients with pulmonary hypertension.

NCT ID: NCT02894970 Not yet recruiting - Clinical trials for Pulmonary Hypertension

A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation

Start date: October 2016
Phase: N/A
Study type: Observational

To evaluate feasibility of photoplethysmography (PPG) of pulmonary arteries in adults children and neonates and to compare normal controls to premature newborns suffering from patent ductus arteriosus and neonates suffering from pulmonary hypertension.

NCT ID: NCT02892981 Completed - Clinical trials for Pulmonary Hypertension

Dead Space Evaluation in Pulmonary Hypertension

Start date: January 2015
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate the role of chemoreceptor activity and ventilation perfusion mismatch on the genesis of exercise induced hyperventilation in Pulmonary hypertension patients. So the investigators tested the chemoreceptor response at rest, both with hypoxic and hypercapnic stimuli, and the ventilatory response during exercise analyzing its two components, alveolar and dead space ventilation.

NCT ID: NCT02886793 Completed - Clinical trials for Pulmonary Hypertension

Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects

PROCLAIM
Start date: June 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are serious diseases with poor prognosis despite recent advances. Currently, pulmonary hypertension (PH) is considered a cell proliferative disorder, which has not been adequately characterized due to the lack of markers. A better understanding of the mechanisms that regulate this proliferative disorder will allow the identification of new therapeutic targets for HP. The objective of the project is to identify cell proliferative processes in severe forms of PH. Patients with PAH (n=20), CTEPH (n=20) and healthy controls (n=20) will undergo characterization of microRNAs (miRNAs) contained within circulating microparticles (MPs) analysis and mitochondrial functionality and FDG-PET to compare cell metabolism in the lungs and the right ventricle between patients and controls.